PERSPECTIVE THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $4.76 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-16
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $4.76, a 39.13% decline from fiscal 2024.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $7.82, a 1600.00% increase from fiscal 2023.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $0.46.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $0.79, a 49.06% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|
| 2025-12-31 | $4.76 10-K · filed 2026-03-16 | ||
| 2024-12-31 | $7.82 10-K/A · filed 2025-03-28 | ||
| 2023-12-31 | $0.46 10-K · filed 2024-03-28 | ||
| 2023-09-30 | $0.45 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $0.64 10-Q · filed 2023-08-11 | ||
| 2022-12-31 | $0.86 10-K · filed 2024-03-28 | ||
| 2022-09-30 | $0.84 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $0.83 10-Q · filed 2023-08-11 | $0.79 10-K · filed 2024-03-28 | |
| 2021-06-30 | $0.53 10-KT · filed 2023-05-01 | ||
| 2020-06-30 | $0.42 10-KT · filed 2023-05-01 | ||
| 2019-06-30 | $0.54 10-K · filed 2021-09-27 | ||
| 2018-06-30 | $0.77 10-K · filed 2020-09-25 | ||
| 2016-06-30 | $1.67 10-K · filed 2018-09-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |